EP0583337A1 - Utilisation d'un lipide pour l'elaboration d'une preparation pharmaceutique enterale destinee au traitement de la malabsorption des lipides. - Google Patents

Utilisation d'un lipide pour l'elaboration d'une preparation pharmaceutique enterale destinee au traitement de la malabsorption des lipides.

Info

Publication number
EP0583337A1
EP0583337A1 EP92910106A EP92910106A EP0583337A1 EP 0583337 A1 EP0583337 A1 EP 0583337A1 EP 92910106 A EP92910106 A EP 92910106A EP 92910106 A EP92910106 A EP 92910106A EP 0583337 A1 EP0583337 A1 EP 0583337A1
Authority
EP
European Patent Office
Prior art keywords
lipid
mlm
lipids
type
malabsorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92910106A
Other languages
German (de)
English (en)
Inventor
Tomas Tage Hansen
Anette MÜLLERTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0583337A1 publication Critical patent/EP0583337A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • the invention comprises a new use of a lipid of a specified kind.
  • the lipid in question is of the type MLM and/or SLS.
  • L which represents a long chain acyl radical, is an acyl radical with 14-24 C atoms, e.g. palmitoyi (CH 3 (CH 2 ) 14 CO-)
  • M which represents a medium chain acyl radical, is an acyl radical with 6-13 C atoms, e.g. pelargoyl (CH 3 (CH 2 ) 7 CO-)
  • S which represents a short chain acyl radical, is an acyl radical with 2-5 C atoms, e.g. valeroyl (CH 3 (CH 2 ) 3 CO-). It is understood that a lipid of the type MLM can be represented as
  • enteral emulsions of lipids of the above indicated type are described, and likewise their use for nutritional purposes. Also, it is described that enteral emulsions of the above indicated type can be used as nutrition for seriously ill patients.
  • the purpose of the invention is to provide other uses for lipids of the above indicated type.
  • the lipids of the above indicated type can be used for treatment of patients with lipid malabsorption, e.g. patients suffering from pancreatic insufficiency, primary biliary cirrhosis or cystic fibrosis, i.e. that those lipids can be used for patients suffering from lipid malabsorption.
  • lipid malabsorption e.g. patients suffering from pancreatic insufficiency, primary biliary cirrhosis or cystic fibrosis, i.e. that those lipids can be used for patients suffering from lipid malabsorption.
  • One category of patients with lipid malabsorption has reduced capability in regard to secretion of pancreatic lipase, which is responsible for the major part of triglyceride hydrolysis in the gut.
  • pancreatic lipase which is responsible for the major part of triglyceride hydrolysis in the gut.
  • Structured lipids of the MLM type is easier hydrolyzed by pancreatic lipase (vide Example 1 ), meaning that even at a very low activity of pancreatic lipase, as in patients suffering from pancreatic insufficiency, the structured lipids of the MLM type will be hydrolyzed, and the formed 2- monoglycerides will be absorbed. It appears from Example 2 that feeding MLM to a pancreatic insufficient pig leads to as much lipid absorption as when feeding soy oil to a pancreatic sufficient pig. A study of pancreatic insufficient rats (vide E ⁇ xample 3) has shown that the total lipid absorption is greater when provided as structured MLM than as randomized MLM or a physical mixture of the corresponding lipids.
  • the content of the essential fatty acid linoleic acid in the lymph was higher in the MLM group, meaning that the total absorption of linoleic acid was higher.
  • the MLM also provides essential fatty acids for the functions of the cell, including formation of membrane lipids and intracellular mediators, e.g. eicosanoids.
  • these results indicate that MLM can be absorbed through the gut mucosa without prior hydrolysis.
  • the use according to the invention of a lipid of the type MLM and/or SLS is for production of a pharmaceutical preparation for treatment of lipid malabsorption.
  • the lipid related to the use according to the invention can be formulated as a part of a dressing or an oil incorporated in the diet or as a part of an emulsion. Typically the lipid should be administered in an amount of 0.5-4.5 g per kg of body weight per day.
  • the use according to the invention relates to lipid malabsorption in both humans and animals.
  • lipid of the type MLM and/or SLS is for patients suffering from lipid malabsorption.
  • the lipid contains more than 20% of lipids of the type MLM. This type of lipid is easily absorbed in the gut. In a preferred embodiment of the use according to the invention the lipid contains more than 10% of lipids of the type SLS. This type of lipid is easily absorbed in the gut.
  • the 5 preparation is formulated as an enteral formulation.
  • lipids of the type MLM or SLS are described, and so are their use as a nutritional agent, and also, use of lipids for treatment of lipid malabsorption are described, but not in relation to lipids of the type MLM or SLS; in particular WO-A-8,902,275 (New England Deaconess Hospital Corp.),
  • Lipids for enteral nutrition of the type LLL can only be absorbed with difficulty by patients suffering from lipid malabsorption. Lipids for enteral nutrition of the type LLL can only be absorbed with difficulty by patients suffering from lipid malabsorption. Lipids for enteral nutrition of
  • MMM cell membranes in the body.
  • the absorption of MMM might be due to a smaller molecular weight and a more compact structure and also a facilitated diffusion across the unstirred water layer of the gut, compared to long chain triglycerides.
  • the lipids of the above indicated type can be absorbed in individuals suffering from pancreatic insufficiency, thus providing essential fatty acids.
  • Lipid emulsions (50 ml) were prepared from 5 ml of lipid, 41 ml of gum arabic (10% w/v) and 4 ml of water and emulsified with Ultra Turrax 3 x 5 minutes at 4°C. The particle size distribution was measured microscopically before and after the titrations.
  • Fig. 2 shows the total lymphatic output.
  • the absorption peak is seen 5 hours after dosage, which is later than when pancreatic lipase and bile is present. After the peak the absorption of MLM continues at a higher level than the two other lipids. This leads to a higher total absorption of MLM.
  • the content of the essential fatty acid linoleic acid in the lymph fractions is shown in Fig. 3.
  • the content of linoleic acid is at a significantly higher level in the MLM group than in the two other groups.
  • the total absorption of linoleic acid is higher in the MLM group.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Le lipide a la/les formules (I) et/ou (II) où L est un radical acyle à chaîne longue, M est un radical acyle à chaîne moyenne et S est un radical acide à chaîne courte. Ce lipide peut être employé avec succès pour l'élaboration d'une préparation pharmaceutique destinée au traitement de l'insuffisance pancréatique, de la cirrhose biliaire primaire ou de la fibrose cystique.
EP92910106A 1991-05-08 1992-05-08 Utilisation d'un lipide pour l'elaboration d'une preparation pharmaceutique enterale destinee au traitement de la malabsorption des lipides. Withdrawn EP0583337A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91610043 1991-05-08
BE9161004 1991-05-08

Publications (1)

Publication Number Publication Date
EP0583337A1 true EP0583337A1 (fr) 1994-02-23

Family

ID=8208778

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92910106A Withdrawn EP0583337A1 (fr) 1991-05-08 1992-05-08 Utilisation d'un lipide pour l'elaboration d'une preparation pharmaceutique enterale destinee au traitement de la malabsorption des lipides.

Country Status (3)

Country Link
EP (1) EP0583337A1 (fr)
JP (1) JPH06507161A (fr)
WO (1) WO1992019237A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503855A (en) * 1992-06-29 1996-04-02 Fuji Oil Company, Limited Freezing-resistant oil-and-fat feedstock, method for producing said feedstock and frozen food containing said feedstock
JP2601104B2 (ja) * 1992-06-29 1997-04-16 不二製油株式会社 耐凍性油脂とその製造方法及び油脂含有冷凍食品
US5681608A (en) * 1993-04-23 1997-10-28 Loders Croklaan B.V. Nutrient fats having improved digestibility
DE69405096T2 (de) * 1993-05-13 1998-01-22 Loders Croklaan Bv Muttermilch-ersatzstoffe aus umgeestertentriglyceridmischungen
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
US20030157237A1 (en) 2001-12-28 2003-08-21 Toshiaki Aoyama Fats and oils composition for reducing lipids in blood
US20120128770A1 (en) * 2009-06-24 2012-05-24 Kobenhavns Universitet Treatment of insulin resistance and obesity by stimulating glp-1 release

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4607052A (en) * 1983-04-15 1986-08-19 Roussel-Uclaf Triglycerides, dietetic and therapeutical applications and compositions containing them
US4847296A (en) * 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
EP0466768B2 (fr) * 1989-04-07 1999-06-30 New England Deaconess Hospital Corporation Triglycerides a chaine courte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9219237A1 *

Also Published As

Publication number Publication date
JPH06507161A (ja) 1994-08-11
WO1992019237A1 (fr) 1992-11-12

Similar Documents

Publication Publication Date Title
US5434183A (en) Phospholipids containing omega-3-fatty acids
US4753963A (en) Nutritional fat suitable for enteral and parenteral products
EP0132089B1 (fr) Compositions d'acide gras
US5059622A (en) Method for reducing blood pressure levels in hypertensive persons
IE83552B1 (en) Phospholipids
EP0374188A1 (fr) Complement dietetique utilisant des melanges d'omega-3/triglycerides a chaine moyenne.
JP4165904B2 (ja) 加水分解最適化脂質エマルジョンおよびその使用
Glavind et al. On the digestion and absorption of lipoperoxides
EP0687418A2 (fr) Composition lipidique, son usage pour normaliser la réponse à un traumatisme
Wilson Studies on the origin of the lipid components of xanthomata
US5922345A (en) Nutrition
EP0583337A1 (fr) Utilisation d'un lipide pour l'elaboration d'une preparation pharmaceutique enterale destinee au traitement de la malabsorption des lipides.
EP0084052A1 (fr) Systeme d'administration de medicaments mi-cellulaires
JPH04290821A (ja) 液体栄養副作用の予防方法またはそれに用いる薬剤の製造方法
IE58891B1 (en) Pharmaceutical and dietary compositions containing linolenic acids for the treatment of benign prostatic hypertrophy
Grancher et al. Studies on the tolerance of medium chain triglycerides in dogs
Wolfram Medium‐chain triglycerides (MCT) for total parenteral nutrition
US20020172710A1 (en) Clinical use of liposome technology for the delivery of nutrients to patients with the short bowel syndrome
Blackburn Nutrition and inflammatory events: highly unsaturated fatty acids (ω-3 vs ω-6) in surgical injury
CA1334002C (fr) Compositions a base d'acides gras essentiels et methodes de modulation de la concentration des prostaglandines chez les mammiferes
Cassidy et al. Lipid accumulation in jejunal and colonic mucosa following chronic cholestyramine (Questran) feeding
JP3947322B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
WO2004108140A1 (fr) Composition pour inhiber la differenciation ou la croissance de cellules adipeuses
Dupont et al. Use of lipids in home parenteral nutrition.
JPH11116473A (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 19970813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971224